-
Clinical Trials & Development1 week agoNovartis Announces Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients with Elevated Lp(a) and Established Cardiovascular Disease (CVD)
Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint...
-
Clinical Trials & Development1 week agoSTAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm.
-
Clinical Trials & Development1 week agoMicro-Bladder Model Demonstrates How Phage Therapy Could Help to Reduce Recurrent UTIs
Researchers used a novel human 3D micro-bladder model to demonstrate how phage therapy could help to reduce recurrent urinary tract infections (UTIs) by attacking the reservoirs...
-
Clinical Trials & Development1 week agoCondition-Specific Meeting Reports and Other Information Related to Patients’ Experience
This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and...
-
Clinical Trials & Development1 week agoAbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
AbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the...
-
Clinical Trials & Development1 week ago
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA...
-
Clinical Trials & Development1 week agoPsilocybin Prevents Chemotherapy-Related Peripheral Neuropathy in Mice
A study found that psilocybin given before chemotherapy prevented the onset of nerve injury in mouse models, even after repeated treatment cycles, and also protected tumor-bearing...
-
Clinical Trials & Development1 week agoSTAT+: Seattle scientists launch $95 million AI biology effort
Ultragenyx drug fails pivotal Phase 3, FDA's success at regulating unproven stem cells, and other biotech news
-
Clinical Trials & Development1 week agoRevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in...
-
Clinical Trials & Development1 week agoSummit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to...
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
